20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Viridian Therapeutics Inc (NASDAQ:VRDN) released preliminary data from its ongoing Phase 1/2 trial of VRDN-001 for chronic thyroid eye disease (TED).
Patients in the 10 mg/kg (n=6) and 3 mg/kg (n=6) cohorts treated with two doses of VRDN-001 were evaluated for changes in proptosis (bulge), CAS, and diplopia (double vision) at week 6.
VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg.
Observed a 50% to 72% reduction in mean Clinical Activity Score (CAS) at week 6 compared with mean baseline levels in patients treated with VRDN-001.
Related: Viridian's Thyroid Eye Disease Candidate Shows Promise At Lower Doses
Five of the twelve VRDN-001 treated patients across both dose cohorts had diplopia at baseline. None of the patients treated with VRDN-001 achieved complete resolution of diplopia at week 6. Investors are probably reacting to this.
VRDN-001 was generally well tolerated by all drug-treated patients in both dose cohorts.
The company also amended its ongoing THRIVE Phase 3 trial design and provided an update on the recent progress of its subcutaneous (SC) program candidates in TED.
THRIVE will now include the VRDN-001 5-dose treatment regimen and placebo arms only. The company expects to announce topline results in mid-2024.
Viridian plans to initiate the THRIVE-2 Phase 3 trial to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED in Q3 2023, with topline data expected by the end of 2024.
Viridian says 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for the company's SC candidates in TED, and it plans to select the lead SC program candidate by year-end 2023 and to advance the program into a pivotal Phase 2/3 trial in mid-2024.
Price Action: VRDN shares are down 18.10% at $20.08 during the premarket session on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!